Technetium Tc99m Sestamibi
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2, Coronary Restenosis
Trial Timeline
Apr 1, 2004 → Dec 1, 2005
NCT ID
NCT00162357About Technetium Tc99m Sestamibi
Technetium Tc99m Sestamibi is a approved stage product being developed by Lantheus Holdings for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT00162357. Target conditions include Diabetes Mellitus, Type 2, Coronary Restenosis.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00162045 | Phase 1/2 | Completed |
| NCT00162331 | Approved | Completed |
| NCT00162357 | Approved | Completed |
| NCT00162344 | Approved | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2